A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers. E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results